Tetra Bio-Pharma announced it decided to moved up the development of its second-generation drug inhalation program.
Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) announced it decided to moved up the development of its second-generation drug inhalation program.
As quoted in the press release:
During the last quarter of 2018, the Corporation began preparations for a research site in the United States to conduct its fibromyalgia clinical trial and we are intent on expanding clinical sites in Canada and in the USA in 2019.
“We previously communicated that after reviewing the human clinical data, Tetra anticipated proceeding into phase 2 clinical trials in fibromyalgia patients,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We are committed to this target and plan to accelerate this development in the USA as well. Tetra has and continues to gain tremendous credibility within the medical community. We earned this credibility because of our clinical studies and exhaustive characterization of the pharmaceutical composition of cannabis-derived smoke and vaporization products. Overall, 2018 was a productive year after completing several clinical trials and we expect 2019 to build on this as we accelerate this program.”